Training Data/
Chai Discovery's Bitter Lesson: Drug Design Is Another Scaling Problem
Chai Discovery argues drug design is a scaling problem: build simpler models, scale data and compute, and verify results in the lab. The episode centers on Chai-2’s jump in antibody hit rate from roughly 0.1% to 15% and the company’s plan to turn discovery into a computer-aided design loop.
